Uncategorized Archives - Page 10 of 13 - IPHA
May 15, 2019

Future Of Medicines Pricing And Supply Will Be ‘Radically Different’, IPHA Tells NCPE Conference

The future of medicines pricing and supply will be radically different to what has gone before – and all stakeholders, especially industry and the State, must […]
May 13, 2019

Ireland Can Be A European Leader In Clinical Trials, IPHA Tells HRB-CRCI Conference

IPHA survey shows it takes about eight months to recruit the first patient into a clinical trial in Ireland Ahead of International Clinical Trials Day, pharmaceutical […]
May 3, 2019

IPHA attends ICHOM annual conference on value based healthcare in Rotterdam.

Orlaith Brennan,  IPHA Director of Commercial Affairs, recently attended the ICHOM annual conference on value based healthcare in Rotterdam. ICHOM is the International Consortium for Healthcare […]
April 26, 2019

Intellectual property must be safeguarded to ensure ongoing breakthroughs in innovative medicines

On World IP Day, pharmaceutical innovators say it’s vital that the intellectual property (IP) rights that enhance the development of innovative medicines in Europe are protected […]
April 8, 2019

New Europe-wide Data Shows New Medicines Face Growing Delays Reaching Irish Patients

New data shows Irish patients face growing delays accessing new medicines, ranking well into the bottom half of European countries surveyed as part of a comprehensive […]
March 28, 2019

IPHA Presses to Place Innovation at the Heart of Europe as Elections Draw Near

As the campaign begins ahead of the European Parliament elections on May 24th, the Irish Pharmaceutical Healthcare Association (IPHA) has called on candidates to back progress […]
March 7, 2019

New Medicines Waited Almost 2.5 Years For Reimbursement Decisions, says IPHA

New figures show 10 innovative treatments approved by the HSE for use by patients spent 890 days awaiting decisions The 10 new innovative medicines recently approved […]
February 28, 2019

Rare Disease Patients Can Access Just One-Third of Medicines Available in Rest of Europe, Says IPHA

Just one-third of medicines for rare diseases licensed for patients in Europe are available in Ireland, according to new figures released on Rare Disease Day by […]
February 25, 2019

IPHA defends industry against ‘baseless’ charge of ‘predatory’ pricing

The Irish Pharmaceutical Healthcare Association (IPHA) has defended the industry against a charge of ‘predatory’ pricing by the National Centre for Pharmoeconomics (NCPE). The NCPE is the […]